The "NewCo" model, where a new company is formed around assets licensed from an existing firm, is a key strategy for Western investors to access a deep well of innovation from Chinese companies like Heisco, which are largely unknown in the West but possess broad, innovative pipelines.

Meta's acquisition of Manus, a Chinese-founded startup that moved to Singapore, is being scrutinized by Beijing. This shows that simply changing legal domicile is not enough to escape China's control over deals involving its domestic technology, data, or talent, setting a precedent for future cross-border M&A.

The most significant sanctions loophole isn't physical chip smuggling but 'compute smuggling.' Chinese firms establish shell companies to build and operate data centers in neutral countries like Malaysia. They then access this cutting-edge compute power remotely, completely bypassing physical import restrictions on advanced hardware.

Meta's $2.5B acquisition of Butterfly Effect shows a playbook for acquiring Chinese-origin tech. By relocating to a neutral country like Singapore, the company becomes palatable for US investment and acquisition, navigating geopolitical regulations and PR backlash, effectively getting "into the democracy bucket."

After decades of being labeled 'IP thieves' by the West, China has adopted open source as a core part of its national tech strategy. This allows the country to legally and legitimately access, use, and build upon global technological advancements without facing accusations of theft.

Contrary to the popular narrative of a monolithic, state-led effort, much of China's technological acquisition was driven by a bottom-up rush. Individual private and state-owned enterprises acted in their own self-interest, proactively seeking out and investing in foreign innovation to bring back home, independent of a central directive.

US officials and AI labs allege Chinese firms are engaged in industrial-scale IP theft. They reportedly use fraudulent accounts to extract capabilities from US models like Claude to train their own, creating a facade of domestic innovation.

Beyond just pharma, China is engaging in a 'salami slicing' strategy to take over the foundational infrastructure of the U.S. biotech economy. This slow, incremental acquisition of manufacturing and research capabilities mirrors its successful long-term strategy for dominating sectors like rare earths.

Bill Gurley highlights a one-way knowledge transfer where Chinese entrepreneurs meticulously study American tech innovation, while their US counterparts largely ignore developments in China. This information asymmetry creates a significant strategic disadvantage for the United States.